15Jun/22
FDA Approved the First Long-acting Complement C5 Inhibitor for the Treatment of Myasthenia Gravis!
On April 28, AstraZeneca released news that its subsidiary Alexion’s new drug Ultomiris (Ravulizumab) was approved by the FDA for the treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) adultRead More…